Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin.
about
Unusual mode of protein binding by a cytotoxic π-arene ruthenium(ii) piano-stool compound containing an O,S-chelating ligandRuthenium anticancer compounds: myths and realities of the emerging metal-based drugs.Ru binding to RNA following treatment with the antimetastatic prodrug NAMI-A in Saccharomyces cerevisiae and in vitroImpact of low- and high-molecular-mass components of human serum on NAMI-A binding to transferrin.Altered DNA binding and amplification of human breast cancer suppressor gene BRCA1 induced by a novel antitumor compound, [Ru(η(6)-p-phenylethacrynate)Cl(2)(pta)].Fighting Cancer with Transition Metal Complexes: From Naked DNA to Protein and Chromatin Targeting Strategies.Antimetastatic activity of novel ruthenium (III) pyridine complexes.Hypoxia-selective inhibition of angiogenesis development by NAMI-A analogues.A ruthenium(ii) based photosensitizer and transferrin complexes enhance photo-physical properties, cell uptake, and photodynamic therapy safety and efficacy.Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activity.Anticancer profile of a series of gold(III) (2-phenyl)pyridine complexes.NAMI-A is highly cytotoxic toward leukaemia cell lines: evidence of inhibition of KCa 3.1 channels.Distinct cellular fates for KP1019 and NAMI-A determined by X-ray fluorescence imaging of single cells.Characterization of a ruthenium(III)/NAMI-A adduct with bovine serum albumin that exhibits a high anti-metastatic activity.RNA-Pt adducts following cisplatin treatment of Saccharomyces cerevisiae.Albumin binding and ligand-exchange processes of the Ru(III) anticancer agent NAMI-A and its bis-DMSO analogue determined by ENDOR spectroscopy.Interaction of anticancer Ru(III) complexes with single stranded and duplex DNA model systems.Molecular mode of action of NKP-1339 - a clinically investigated ruthenium-based drug - involves ER- and ROS-related effects in colon carcinoma cell lines.EPR as a probe of the intracellular speciation of ruthenium(III) anticancer compounds.Simultaneous observation of the metabolism of cisplatin and NAMI-A in human plasma in vitro by SEC-ICP-AES.
P2860
Q27720200-496D05C3-D166-4690-9BB8-B64ED04C410FQ30403317-100480D3-6C32-4814-B05C-82696D8A45D8Q33955538-5B0C5340-5A39-4D79-8F17-8C29B45FB27DQ35621511-AAD1C8E9-7822-4BD9-8F7F-33D30929A03FQ36396542-7E1BD08C-AECE-4721-A324-C938CF53D58DQ37337277-2E381271-204E-4672-8527-13D78C3DA89BQ37373102-8B24D602-0304-4CF3-9902-2812C80FB024Q37424157-CA4F03B7-F22E-4F2A-9221-ADBDD2E999FCQ38788535-3F906292-4457-4C75-84B6-CDD7C0E5C698Q38930683-810EC360-E549-463D-BCB4-E30A0A360340Q38942097-B660AFA8-94ED-4C46-8C62-50974ABEB545Q38979908-0AC862A5-92AD-4849-8835-F98071C23C14Q39294174-38649BCB-CAF7-465C-80EA-B632022FDD9FQ39744502-7681888F-6129-439A-A1AB-09122B65407CQ40560075-E7823346-BEBC-41D1-AC82-4B6BD7E956D1Q40737623-11547D8D-9477-4C50-AEC1-6C674BE10C95Q40759010-400EDB42-E762-4F82-BF65-C3B5DADAE305Q41134989-CE63EBDD-60D9-4925-9D4F-3BBBCFBB2BEBQ43811304-117DBC79-157F-437B-842D-7CDC1B2641A5Q51756809-93AE7E4F-7685-4006-ABA6-A45A4BF56E6C
P2860
Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Biological role of adduct form ...... albumin and serum transferrin.
@en
type
label
Biological role of adduct form ...... albumin and serum transferrin.
@en
prefLabel
Biological role of adduct form ...... albumin and serum transferrin.
@en
P2093
P356
P1476
Biological role of adduct form ...... albumin and serum transferrin
@en
P2093
F Piccioli
M Cocchietto
P2888
P304
P356
10.1023/A:1026243000320
P577
2003-11-01T00:00:00Z
P6179
1038985851